Form 4 for ORGO Organogenesis Holdings Inc.
Accepted 2022-07-01 00:00:00 ET · period of report 2022-06-30 · accession 0001062993-22-015767 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-07-01 | 2022-06-30 | ORGO | Gillheeney Gary S. | Pres, CEO, Dir | M - OptEx | $0.99 | +505.1K | 903.3K | +127% | +$500.0K |
| D | 2022-07-01 | 2022-06-30 | ORGO | Gillheeney Gary S. | Pres, CEO, Dir | M - OptEx | $0.00 | -505.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-06-30 | M | A | 505,050 | $0.99 | 903,292 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-06-30 | M | D | 505,050 | $0.00 | 0 | D | $0.99 · — to 2023-07-25 | 505,050 Class A Common Stock | (F1) 100% of the shares subject to the option are fully vested and exercisable. |